The prohibition of serious contamination such as pneumonia, meningitis, and bloodstream contamination are driving the US pneumococcal vaccine market.

NEW YORK CITY, NY, UNITED STATES, December 10, 2024 /EINPresswire.com/ -- The US pneumococcal vaccine market report assesses the competitive scenario of the market, examining all the established players and new market entrants.

The market for the US pneumococcal vaccine is on a growth trajectory. The market, valued at USD 5,239.27 million in 2024, is poised to reach USD 6,511.79 million by 2034. It is anticipated to register a CAGR of 2.3% from 2025 to 2034.

𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧:

Pneumococcal vaccine is a vaccine to prohibit pneumococcus bacteria contamination. These bacteria are a prominent cause of ear contamination, strep throat contamination, grave pneumonia, meningitis, or blood contamination globally. These vaccines assist the body to generate antibodies that assist the body to protect against these bacteria. This vaccine is approved for persons two years of age and adults with health issues.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐞 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.polarismarketresearch.com/industry-analysis/us-pneumococcal-vaccine-market/request-for-sample?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01

The vaccine is for injection into a muscle or beneath the skin. It is provided by a healthcare expert. A replica of Vaccine Information Statements will be provided prior to each vaccination. One should converse with the pediatrician in the context of the usage of this medicine in children. Growing public consciousness and the usage of FDA-consented licensed vaccines in the US contribute to the development of the vaccine, impacting the US pneumococcal vaccine market demand favorably.

𝐊𝐞𝐲 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:

• The US pneumococcal vaccine market size is valued at USD 5,239.27 million in 2024 and is projected to grow to USD 6,511.79 million by 2034.

• The elevated existence of pneumococcal contamination fuels the need for pneumococcal vaccines in the US.

• The market segmentation is primarily based on product type, vaccine type, and end use.

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞:

The US pneumococcal vaccine market is portrayed by competitiveness. The top market contenders, such as
• Pfizer Inc.
• Merck & Co., Inc.
• Sanofi
• GlaxoSmithKline plc
• CSL Behring
• Serum Institute
• Astellas Pharma US, Inc.
• Johnson & Johnson
• Novavax, Inc.
• Vaxcyte, Inc.

Also, they support strategic alliances to enhance research potential and drive invention. Here are some of the major market developments:

• In March 2024, Vaxcyte, Inc. triumphantly recorded contenders in their trial while examining VAX-24, a pneumococcal conjugate vaccine (PCV) comprised of 24 valences that are examined amidst healthy babies.

• In October 2023, Lonza and Vaxcyte, a US clinical-stage vaccine invention firm, augmented their alliances to escalate manufacturing facility Vaxcyte's pneumococcal conjugate vaccine (PCV) contenders.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐚 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐨𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐁𝐞𝐟𝐨𝐫𝐞 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞:
https://www.polarismarketresearch.com/industry-analysis/us-pneumococcal-vaccine-market/request-for-discount-pricing?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01

𝐆𝐫𝐨𝐰𝐭𝐡 𝐃𝐫𝐢𝐯𝐞𝐫𝐬 𝐚𝐧𝐝 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬:

𝐆𝐫𝐨𝐰𝐢𝐧𝐠 𝐏𝐫𝐞𝐯𝐚𝐥𝐞𝐧𝐜𝐞 𝐨𝐟 𝐏𝐧𝐞𝐮𝐦𝐨𝐜𝐨𝐜𝐜𝐚𝐥 𝐂𝐨𝐧𝐭𝐚𝐦𝐢𝐧𝐚𝐭𝐢𝐨𝐧: The elevated existence of pneumococcal contamination and the robust dissemination framework in the US drives the market notably fueling the US pneumococcal vaccine market growth. Additionally, the escalating pneumococcal vaccinated population supplementally eases the market.

𝐆𝐫𝐨𝐰𝐢𝐧𝐠 𝐃𝐞𝐦𝐚𝐧𝐝 𝐟𝐨𝐫 𝐏𝐧𝐞𝐮𝐦𝐨𝐜𝐨𝐜𝐜𝐚𝐥 𝐕𝐚𝐜𝐜𝐢𝐧𝐞𝐬: The growing demand for pneumococcal vaccines is pushing notable growth in the US market due to several elements such as growing consciousness of vaccine advantages, growing existence of respiratory illnesses, healthcare policy reinforcement, and maturing population with elevated probabilities. Pneumococcal illnesses involving pneumonia, meningitis, and bloodstream contaminations are surging, particularly among susceptible groups such as elderly people, babies, and persons with eroded immune systems.

𝐆𝐫𝐨𝐰𝐢𝐧𝐠 𝐀𝐠𝐠𝐫𝐞𝐠𝐚𝐭𝐞 𝐨𝐟 𝐄𝐥𝐝𝐞𝐫𝐥𝐲 𝐏𝐞𝐨𝐩𝐥𝐞: The growing aggregate of elderly persons in the US is fueling the demand for pneumococcal vaccines. Elderly persons encounter a notably higher probability of grave pneumococcal illnesses such as pneumonia, meningitis, and bloodstream contamination because of their fragile immune systems. Thus, as the elderly population escalates and the longevity of people grows, there is an elevated requirement for prohibitive healthcare involving vaccines.

𝐈𝐧𝐪𝐮𝐢𝐫𝐞 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐁𝐞𝐟𝐨𝐫𝐞 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞:
https://www.polarismarketresearch.com/industry-analysis/us-pneumococcal-vaccine-market/inquire-before-buying?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰:
By Product Type Outlook
• Prevnar 13
• Synflorix
• Pneumovax23

By Vaccine Type Outlook
• Pneumococcal conjugate vaccine (PCV)
• Pneumococcal polysaccharide vaccine (PPV)

By End Use Outlook
• Public Sector
• Private Sector

𝐁𝐫𝐨𝐰𝐬𝐞 𝐏𝐌𝐑'𝐬 𝐔𝐒 𝐏𝐧𝐞𝐮𝐦𝐨𝐜𝐨𝐜𝐜𝐚𝐥 𝐕𝐚𝐜𝐜𝐢𝐧𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐂𝐨𝐯𝐞𝐫𝐚𝐠𝐞 𝐟𝐫𝐨𝐦 𝐃𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭 𝐏𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬:
US Pneumococcal Vaccine Industry Projected to Reach $6,511.79 Million by 2034, Growing at a CAGR of 2.3%

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:
Digestive & Intestinal Remedies Market:
https://www.polarismarketresearch.com/industry-analysis/digestive-and-intestinal-remedies-market

Arthroscopy Market:
https://www.polarismarketresearch.com/industry-analysis/arthroscopy-market

Angina Pectoris Drugs Market:
https://www.polarismarketresearch.com/industry-analysis/angina-pectoris-drugs-market

Liposomal Doxorubicin Market:
https://www.polarismarketresearch.com/industry-analysis/liposomal-doxorubicin-market

Surgical Sponges Market:
https://www.polarismarketresearch.com/industry-analysis/surgical-sponges-market

𝐀𝐛𝐨𝐮𝐭 𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 & 𝐂𝐨𝐧𝐬𝐮𝐥𝐭𝐢𝐧𝐠, 𝐈𝐧𝐜:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR’s clientele spread across different enterprises. We at Polaris are obliged to serve PMR’s diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR’s customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR’s customers.

Likhil G
Polaris Market Research and Consulting
+1 929-297-9727
sales@polarismarketresearch.com
Visit us on social media:
Facebook
X
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.